Gabelli Funds LLC Buys 11,100 Shares of DexCom, Inc. $DXCM

Gabelli Funds LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 22.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,300 shares of the medical device company’s stock after purchasing an additional 11,100 shares during the period. Gabelli Funds LLC’s holdings in DexCom were worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Trust Co. of Vermont increased its position in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares in the last quarter. IFP Advisors Inc boosted its holdings in DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. Finally, Keel Point LLC grew its stake in DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after acquiring an additional 193 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $74.85 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business has a 50-day simple moving average of $72.79 and a two-hundred day simple moving average of $69.01. The company has a market capitalization of $28.88 billion, a P/E ratio of 31.99, a price-to-earnings-growth ratio of 1.21 and a beta of 1.45. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $0.32 earnings per share. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. Research analysts expect that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock valued at $7,205,258 in the last three months. Insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Robert W. Baird set a $80.00 target price on DexCom in a report on Friday, May 1st. Mizuho lifted their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Benchmark restated a “buy” rating on shares of DexCom in a research note on Tuesday, June 23rd. Finally, Piper Sandler restated an “overweight” rating and set a $88.00 price objective (up from $75.00) on shares of DexCom in a report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.40.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.